‘Game-changing’ treatment for prostate cancer could become available to patients

Scientists part funded by Worldwide Cancer Research have tested close to 1000 existing medicines and discovered that a cheap drug commonly used to treat parasitic worm infection could be a game-changing treatment for prostate cancer.

We are currently developing a clinical study design that will be able to determine the best dose and administration schedule to be used along with docetaxel. The aim would be to allow the drugs to work together while producing the lowest side effects. Once this has been shown to be effective in treating prostate cancer, the combination treatment could be adopted widely in patients with prostate cancer. 

Professor Hing Leung Institute of Cancer Sciences at the University of Glasgow

The drug, called mebendazole, is on the World Health Organisation’s List of Essential Medicines and can be purchased from a pharmacist for less than £2 per pill.

The study from the laboratory of Professor Hing Leung was funded by Worldwide Cancer Research, alongside the Prostate Cancer Foundation and Cancer Research UK.

Recently published in the British Journal of Cancer, the study found that mebendazole worked in combination with the commonly used chemotherapy drug docetaxel to enhance its ability to kill prostate cancer cells and abolished tumour growth in mouse models of prostate cancer.

The researchers found that mebendazole and docetaxel work together to kill prostate cancer cells by disrupting the molecular “scaffold” used by cells to divide. This scaffold is vital for cancer cells to grow and divide and the combination treatment was found to drastically increase cancer cell death.

Drug repurposing finds new ways to use existing drugs and fast tracks the process of testing new treatments as the drugs tested have already been used in humans with satisfactory safety records. This makes drug repurposing more time and cost-effective than developing new drugs.

This research could be a real game-changer for prostate cancer patients. Docetaxel is the main chemotherapy used to treat prostate cancer, but many patients end up developing resistance to the drug and their cancer comes back. This bold new idea shows how we can use already existing medicines to bolster the effects of chemotherapy and hopefully improve outcomes for people with prostate cancer. We are excited to follow the progress of the research team as they take their work forward into clinical trials.

Dr Helen Rippon Worldwide Cancer Research Chief Executive

Donate now & become a Curestarter

Be part of a united effort to stop lives being cut short by cancer.

Related news

A shot of Ruth Ganss in the lab, holding a pipette and looking straight at the camera
News and press
A new approach to drug dosage could help tackle hard-to-treat cancers
Researchers find a 'less is more' approach to drug dosage could help tackle hard-to-treat cancers
News and press
Researchers make a crucial new lung cancer discovery
Researchers make a crucial new lung cancer discovery
News and press
Remember a Charity Week 2024
Remember a Charity Week
Share this page